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ABSTRACT: Traumatic brain injury is a leading cause of mortality
worldwide, often affecting individuals at their most economically
active yet no primary disease-modifying interventions exist for their
treatment. Real-time direct spectroscopic examination of the brain
tissue within the context of traumatic brain injury has the potential to
improve the understanding of injury heterogeneity and subtypes,
better target management strategies and organ penetrance of
pharmacological agents, identify novel targets for intervention, and
allow a clearer understanding of fundamental biochemistry evolution.
Here, a novel device is designed and engineered, delivering Raman
spectroscopy-based measurements from the brain through clinically
established cranial access techniques. Device prototyping is undertaken within the constraints imposed by the acquisition and site
dimensions (standard intracranial access holes, probe’s dimensions), and an artificial skull anatomical model with cortical impact is
developed. The device shows a good agreement with the data acquired via a standard commercial Raman, and the spectra measured
are comparable in terms of quality and detectable bands to the established traumatic brain injury model. The developed proof-of-
concept device demonstrates the feasibility for real-time optical brain spectroscopic interface while removing the noise of extracranial
tissue and with further optimization and in vivo validation, such technology will be directly translatable for integration into currently
available standards of neurological care.
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■ INTRODUCTION
Rapid in vivo healthcare point-of-care diagnostics are of critical
importance to clinical medicine. They aid in providing
optimized, individually tailored, efficient treatment. Currently,
no primary disease modifying interventions exist for the
treatment of traumatic brain injury (TBI).1,2 Clinical manage-
ment is primarily directed toward the normalization of the
intracranial environment, be it pressure, perfusion, or oxygen-
ation.2 The maintenance of effective intracranial homeostasis is
aimed at minimizing secondary brain injury and providing the
most favorable conditions for the preservation of neurological
tissue. Invasive (placed into brain tissue) monitoring modal-
ities including pressure transducers and oxygen tension sensors
are used to provide data to support the maintenance of such
favorable physiological conditions. As independent parameters,
both intracranial pressure (ICP) and brain tissue oxygen-
tension guided intervention provide minimal improvement in
outcome after severe TBI.3,4 The pathophysiology of injury
evolution is multi-faceted and currently not understood well
enough to provide effective pharmacological targeting to
reduce injury burden or progression. Surgical intervention
has demonstrated a role in saving lives; however, it is unclear as
to what extent the outcome is improved in individuals who
survive.5,6 One of the reasons often attributed to the modest
improvements in outcome observed after surgical intervention
is the course stratification systems currently in place for
classifying TBI. The Glasgow Coma Scale (GCS) and Marshall
CT grading system are among the most common grading tools
used to quantify the severity of injury burden.7 Through these
tools (along chiefly with ICP measurement), interventions and
management plans are formulated. It is often postulated that a
more in-depth understanding of the biochemical injury
evolution within individual patients may allow existing
interventions to be used more effectively, along with the
identification of novel pharmacological and non-pharmaco-
logical therapeutic targets. Quantitative measurement of a
patient’s disease burden via condition specific biomarkers is
crucial in modern practice to guide tactful therapeutic
treatment.8 Disease-indicative biomarkers provide insights
into the biological pathways underpinning certain pathologies
allowing effective stratification and classification of pathology
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for the purpose of guiding management.9 However, typical
time-to-results of many diagnostic and prognostic tests specific
to TBI such as diffusion tension magnetic resonance imaging
(MRI) and neuro-cognitive assessment (NAB battery) can be
greater than 13 weeks,10 with as much as 10 weeks being a
common representative time.11 In the scope of critical care,
such untimeliness provides a barrier to effective management
guidance.
TBI constitutes a major burden to healthcare services.
Globally, it is the most common cause of death in those below
45 years of age. In 2017, there were 531 admissions with a TBI
per 100,000 individuals in the UK alone.1,12 These numbers
however are typically only inclusive of the cases that present to
secondary care. If cases that did not present to emergency
departments are included, the actual incidence of TBI in
developed nations is around 790 cases per 100,000 per year.13
The emotional and functional impacts on patients and their
families are life changing, with large subsequent direct and
indirect costs associated with acute and community care.14
However, the real cost of injury is far further in reach, with the
life medical, educational, and social cost of care for a pediatric
case of TBI estimated to be in the region of £4.9 million,15
with the total annual cost globally in the region of £43
billion.16 The pathophysiology of TBI is complex and broadly
separated into primary and secondary insults. The primary
insult is underpinned by a momentum transfer to the brain
from either the direct cause of injury, for example, a strike to
the head or the skull itself.17 The secondary insult is
considerably more complex. It is a pathophysiological cascade
similar to a chain reaction. Many of the pathologies detailed
are interrelated, with one proliferating the other. For example,
a decoupling of cerebral blood flow and metabolism propagates
oxidative stress and excessive glutamatergic excitation, which
can lead to neuro-inflammation and programmes of cell death.
In the context of severe TBI, these processes often lead to
cerebral swelling and raised ICP. Cerebral oedema (CO)
evolving as a result of secondary insult plays a key role in the
development of raised ICP. Other pathological processes may
occur concurrently, such as hydrocephalus, where the
accumulation of cerebrospinal fluid (CSF) contributes to
high ICP, along with the distortion of important neuro
anatomical structures leading to tissue injury.18 Although it is
well-established that the ICP is a key target for intervention
and management, current options often confront the specific
parameter of abnormal ICP and neglect the underlying
biological pathways, such as in CO. In such cases, a craniotomy
or CSF diversion is used to reduce pressureproviding
volume for the brain to swell and limiting any increase in the
ICP, although not addressing the underlying causes that have
led to this situation.
In the past decade, several serum biomarkers have been
showing promise as potential candidates to provide insights
into the pathophysiology of TBIs and their associated
neurodegeneration, particularly S100B, UCHL1, NAA, and
NFP.19−22 Some biomarkers that have demonstrated robust
correlation with TBI outcomes have been identified in difficult-
to-sample fluids such as CSF. Within this fluid, numerous
biomarkers have demonstrated exciting utility, specifically
correlating with severity of injury as evaluated by the GCS.23
The in vitro analysis of serum and CSF samples of 98 serum
biomarkers in one investigation correlated with the level of
severity, with 49 of which predicting the patients’ outcome.23
Studies such as this demonstrate the potential of use of
biofluid-based assays and sensing methods. The clear
advantages of point-of-care diagnostics for acute diseases and
especially TBI ultimately offer guidance for tactful healthcare
management. Specifically, within the context of TBI, a clearer
understanding of when to utilize current pharmacological and
surgical intervention would be of great value. Multiple
previously trailed interventions, which demonstrated promising
pre-clinical effect failed to translate this into tangible
improvements in outcome in controlled trials.23 More specific
pathology-based stratification or classification of injuries may
allow better sub-group targeting of these therapeutics and
produce the improvements in clinical outcome that was
anticipated.
Concurrently, Raman spectroscopy is a sensitive analytical
method, which provides a unique spectral fingerprint of target
analytes via the inelastic scattering of light. In contrast to the in
vitro bioassays, its portability enables reliable in vivo point-of-
care diagnostics to be conducted. Raman spectroscopy can
offer a label-free mechanism for measuring changes to
biochemistry, which can be applied in vivo in invasive settings
such as surgery, which has also shown promise for non-invasive
measurements. In neurology, there has been an emphasis on
using Raman spectroscopy for cancer detection, as an
interoperative guide during tumor resection.24−26 This was
motivated to a degree by the diffuse nature of glioblastomas,
where discrepancies between preoperative MRI scans lead to
relapse from the resection margin. Further, the availability of
commercial portable Raman devices for industrial applications
enables the proof-of-concept interventions using Raman
spectroscopy as well as the relatively straightforward
integration into existing surgical practice and healthcare
pathways. This concept is further highlighted across several
publications by Jermyn et al.,25,27,28 where the probe developed
featured a compact concentric design, with a central excitation
illumination fiber and peripheral collection fibers, which
allowed for its integration into the existing surgical practice.
By comparison to MRI, the use of Raman spectroscopy
showed a greater specificity and sensitivity, centimeters beyond
the region of detection using the radiological scans. Following
the initial study, the researchers performed ex vivo validation
that combined several different animal models and devices.
Desroches et al.24 extended the initial concept to show that
high wavenumber bands alone can be used in the classification
of cancerous tissue. The authors also have shown that the need
to manually subtract background effects caused by fluorescent
lights in the operating theatre can be ignored by using machine
learning.28 Raman spectroscopy was also applied to study the
different brain structures, with clear differences observable in
the spectra of white matter and gray matter. The work by Kast
et al.29 showed that Raman bands displaying key changes for
white matter and gray matter come from a mixture of lipids
and proteins. A similar analysis was performed by Koljenovic ́ et
al.,30 using falsely colored Raman image maps of tissue from
both brain and bladder in a porcine model. The authors noted
design considerations when using fiber optics, which allowed
for the bulk laser and the spectrometer setup to be kept away
from tissue and patient measurements as discussed previously
in the work by Desroches et al.24 Raman spectroscopy has been
shown to be further sensitive to conformational changes in
proteins, which have important implications for neuro-
degenerative diseases such as Alzheimer’s and Parkinson’s. Ji
et al.31 showed a blueshift of 10 cm−1 to the amide I band as a
result of misfolded proteins in a murine model of Alzheimer’s
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disease. Flynn et al.32 studied the formation of αsynuclein
amyloid fibrils associated with Parkinson’s disease, as they
aggregate from solution under differing pH levels and for
mutant forms of the protein linked to early onset of the
disease. The first experiment showing that Raman spectrosco-
py is sensitive to biochemical changes following TBI was
performed by Tay et al.33 using a focal brain injury model (left
motor cortex) in mice. Dramatic changes were observed in the
spectral profile in response to injury, using the uninjured
hemisphere as a control. Although the Raman analysis in this
study was purely qualitative, immunohistology studies were
also performed, showing that the observed changes may be
linked to mitochondrial activity and apoptosis following
injury.33 More recent work by Surmacki et al.34 has studied
the temporal response to TBI at 2 and 7 days after injury in a
murine model. In addition to changes from the hemisphere of
injury, spectral changes were also observed from the
contralateral hemisphere and seen to evolve with time. Unlike
the previous study, attribution to the underlying biochemistry
was made with reference to Raman spectra of brain specific
lipids to make qualitative attribution to a relative increase in
cholesterol with injury. Recently, Raman spectroscopy
combined with advanced machine learning was applied to
investigate whether the retina can reflect the brain micro-
environment after TBI,39 in a clinically relevant murine model,
showing that spectra from the eye can distinguish moderate
TBI and severe TBI from a sham group, and show this to be as
a result of similar chemical changes to those seen at the point
of injury on the brain with the detected changes identified
being largely due to metabolic distress and the release of
cardiolipin, consistent with the use of mass spectrometry as a
diagnostic modality for TBI.35 While mass spectrometry can
provide superior molecular discrimination, Raman spectrosco-
py has the advantage of being both a portable and
nondestructive technique with many ongoing efforts in the
field for translation into in vivo measurements and diagnostics.
Raman spectroscopy, therefore, enables rapid and specific
quantitative analysis of chemical composition and structure,
requires no complex sample preparation or defined sample size
with an inherent ease of detection in aqueous conditions.36,37
Of an importance, is its non-destructive nature, posing it as
ideal for use in clinical settings where deploying Raman-based
technology can enable differentiation between disease and
healthy tissue states during the neurosurgery.38 As such, in
conjunction with the emergence of state-of-the-art machine
learning techniques, the development of reliable, rapid Raman-
based in vivo diagnostic tools ultimately promises better quality
of patient treatment. While Raman spectra define a
biochemical fingerprint, uniquely determined by the under-
lying molecular constituents, the spectral interpretation due to
the biological samples’ complexity is not trivial. Recently, we
developed a machine learning technique based on the self-
optimizing Kohonen index network (SKiNET) for simulta-
neously providing rich information and classification from
complex biological matrices, even with noisy or poor-quality
spectra with very subtle differences that would result from a
low laser power and short acquisition times required in
intraoperative or diagnostic applications of Raman spectros-
copy.39
Herein, we report the development of a Raman probe-based
device, which utilizes the specificity of inelastic scatter in
conjunction with access to CSF and brain tissue provided by
standard cranial access techniques40 undertaken in approx-
imately 15−20% of TBI admissions to secondary care.41 The
purpose of which would be to temporally track the pathology
and injury evolution of moderate to severe TBI (for which
intracranial access is mandated), generating a “real-time” brain
optical interface. Using three-dimensionally printed intracranial
bolt with mechanical stress test simulations for auto tapping
thread, a prototype device is developed for these purposes and
tested using anatomically correct skull model. The design
incorporates off the shelf Raman probe, and spectral response
is demonstrated via the direct comparison to commercial
Raman system. Single-use disposable bolts with quartz
windows permit reusable procedure of the probe. This
Raman device combined with our versatile SKiNET algorithm
enables the capability to discern between TBI and healthy
groups. The self-organizing map (SOM) discriminant index
(SOMDI) for each injury state uniquely provides further
insights into the biological spectral features responsible for
clusters observed, and the regression fitting adds further depth
allowing to quantitatively attribute changes in the underlying
biochemistry. The developed proof-of-concept device demon-
strates the feasibility for real-time optical brain spectroscopic
interface removing the noise of extracranial tissue, which after
successful optimization, in vivo validation, and clinical trial can
be translatable into current standard of care. The results from
this study thus lay a platform to aid in the long-term the tactful
therapeutic management, which can also provide important
clinical insights into the pathophysiological cascades. This in
turn will further enable better-quality post neurotraumatic care
as well as the development of novel pharmaceutical and
physical therapies.
■ MATERIALS AND METHODS
Materials. Fabrication of device prototypes was undertaken using
RS PRO 2.85 mm natural poly(vinyl alcohol) (PVA) 3D printer
filament, RS PRO 2.85 mm black acrylonitrile butadiene styrene
(ABS) 3D printer filament, and RS PRO 2.85 mm white ABS 3D
printer filament. The PVA filament was used exclusively in the
generation of support during the printing process. Polystyrene was
purchased from Sigma-Aldrich. The polished disc was acquired from
Robson Scientific. Murine species subjected to craniotomy following
induction of controlled cortical impact injury are described in refs.39,42
Three days after the TBI the brain was removed and post-fixed in
sodium chloride saline and the cortex (neocortex) tissues were used
for spectroscopic studies. The ethical framework for the laboratory (in
vitro) consists of the Home Office license for the sacrifice of murine
species (Sprague Dawley rats). The clinical and iCal frameworks
comprise the red diamond ethics (ERN_17-0916) part of the NIHR
portfolio study.
Design and Fabrication of 3D Printed Elements. The
fabrication of the 3D printed elements detailed utilized Autodesk
Fusion 360 (AF360) software. AF360 is an integrated computer-aided
design (CAD), engineering (CAE), and manufacturing software,
which in conjunction with Cura software and an Ultimaker S3 fused
filament fabrication (FFF) printer facilitates rapid design, preliminary
testing, and manufacture of prototype components. To ensure against
the risk of infection, the device prototype was designed to seal the
cerebral matter from the external environment. This was facilitated by
inclusion of a 10 mm diameter quartz polished disc.
Finite Element Analysis. Finite element analysis (FEA) was
conducted through the CAD and CAE tools featured within AF360.
Such tools are broadly encompassed by the fields of FEA and
computational fluid dynamics. The AF360 software enabled the
inherent ease of FEA under its simulation feature. Implementation of
the tests followed specific configurations, underpinned by constraints,
loads, and contacts (friction) as following: all comparative simulations
proceeded on the basis of the same constraints and load; and, in
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AF360, implementation of constraints was carried out with the aim of
ensuring the static stability of the model, without impeding
deformation. As such, constraints were only applied to the frontal
bone and all faces were fixed, except the internal faces of the proposed
craniotomy site. This left the proposed medical device completely free
and unconstrained to deform as it would in situ. All loads applied in
simulation were applied directly to the probe housing. This force was
shared equally between the four baffles incorporated into the
structure, to mimic the torque provided by the tightening clip. One
of the most important aspects of the simulation definition was the
generation of friction between the probe housing and craniotomy site.
The site itself was designed as the exact female part to the device’s
thread. Although a simplification, this has enabled the inhibition of
interference of the two components but ensured contact between
them. In testing, a coefficient of friction of 0.9 was used as guided by
the literature.43
Acquisition of Spectral Data. Acquisition of probe data was
made using the InPhotonics Raman probe II, an InPhochelle charge
coupled device spectrometer with 785 nm laser and the device
detailed. The probe consisted of permanently aligned combination of
two single fibers (100 μm excitation fiber, 200 μm collection fiber)
with filtering and steering micro-optics, NA 0.22, with stainless-steel
cabled fiber with a design to filter laser line and quartz spectral
contributions from both input and output fibers (O.D. > 8 at laser
line). Samples were loaded into the holder internal to the skull model
with the probe aligned via the clip mechanism. The spectra were
acquired at a laser power of 20 mW and 20 s acquisition time with 15
accumulations at 7.5 mm distance of the probe from the sample.
MATLAB R2019a was used to resample and truncate the probe
spectra. Negative least squares fitting, against each average spectra
using lipid data from ref 44 loaded as components into the analysis
tool in WiRE are detailed in refs 39a and 39b. Processing of spectra
was performed in WiRE 5.1, with cosmic rays removed from each
scan using the nearest neighbor method, followed by the baseline
subtraction using the “intelligent spline” fitting with 11 nodes.
Data Processing and Multivariate Analysis. Multi-variate
analysis was performed using the SKiNET based on SOMs, described
in detail in refs 39a and 39b. SOMs are a single-layer artificial neural
network that are represented as a 2D hexagonal array of neurons.
Inspired by the visual cortex in the brain, the SOM is trained so that
neighboring neurons activate according to similar inputs, in this case,
Raman spectra. Each neuron has a weight vector with length equal to
the number of variables in a spectrum. Through exposing the network
to training samples over a number of iterations, the weights are
gradually adjusted to be similar to the input data, so that each neuron
only activates on a given spectral signature. The result is a projection
of hyperspectral data into 2D space that can be shown as visible
clustering according to tissue type and injury state. SKiNET employs
the SOMDI, which appends a set of label vectors to each neuron and
allows us to study the most prominent features that cause the
activation of a particular neuron to a class label. Subsequently, a
supervised learning step is introduced to optimize the network, and
the class label associated with each neuron is used to quickly identify
new data presented to the SOM, allowing for diagnostics. Raw
component spectra from brain specific lipids were fitted to SOMDI
for a particular state, constituting a physically realistic fit, as our
Raman spectra represent a mixed state of positive contributions from
constituent components. The change in fitting coefficients were used
to interpret the compositional changes to tissue in response to the
injury.
■ RESULTS
The initial device development was orientated around the
physical constraints of the probe and cranial access device
dimensions (Table 1). The craniotomy site is typically created
via a disposable clutched perforator drill bit.45 In order to
prevent the surgeon from drilling into the tissue, the drill
should allow for an internal ledge. This also will provide a
change in geometry throughout the site. Because of the
potentially raised ICP, the design should also consider
variations in the degree of brain swelling. A higher ICP
means the brain would occupy a greater volume within the
calvarium and sub-dural spaces. Therefore, design should
include a mechanism to enable fine tuning of the device
position to preserve the working distance of the probe and
maximize the signal quality. Given these constraints, several
key factors need to be taken into consideration upon designing
the probe including, the fine-tuning of probe working distance
from the brain, secure and safe positioning within the calvarial
bone, (Table 1 and Figure 1) alignment of the probe within
the device, closure of the brain to the external environment,
material selection, which ensures biocompatibility while
avoiding fracture, facile, cheap, and repeatable manufacturing
and the quantification of design through FEA.
A FFF 3D printer was exploited for the prototyping because
of its reliability, safety, low cost, and simplicity.46 Thermo-
plastic polylactide was utilized as a biocompatible filament and
AF360 software for design (Figure S1). The initial design
targeted fine-tuning and preservation of the probe’s working
distance. A self-tapping 3D printed thread was used to enable
fine adjustment to the position of the probe within the
craniotomy site.
This was combined with a supportive housing to prevent
damage. However, the probe support yielded an apparent
instability. Given that skull is not a planar surface and the
added mass of the support increases the moment around the
bolt, a simplification of the design was subsequently
implemented, and the support was removed. This enabled
safe and secure positioning within the frontal bone while
minimizing the resource intensity. Further optimization of
secure positioning within the frontal bone as well as alignment
of the probe within the device was achieved via integration of
the bolt with an alignment clip. Integration of the components
was aided via the addition of baffles on the external surface of
the holder (Figure 1). Through the incorporation of two M2.5
× 0.35 screws, the clip acted as both a tightening mechanism
and a method for alignment (Figures 1c and S1).
To minimize the risk of infection, isolation of the brain to
the external environment is crucial. This was tackled by the
fashioning of a ledge internal to the holder (Figure 1c) and
inclusion of a sunken template for the insertion of a 10 mm
diameter quartz disc. Quartz is an ideal candidate material for
this purpose because of the little Raman signal at 785 nm
(enhanced by its location, far out of focus, and immediately
Table 1. Probe and Craniotomy Site Design Specifications,
Shown in Three Dimensions in Figure 1 for Visualization of
How the Constraining Parameters Guided the Device
Designa
Raman probe





13.7 upper internal diameter
(mm)
14.5





7.5 total length of site (mm) 7.0
laser wavelength
(nm)
785 length of safety ledge
(mm)
2.0
aThe upper and lower site diameter inform the major and minor
diameter of bolt, respectively, and constraints on site length in
conjunction with variability in brain swelling inform its length [Figure
1a(i)].
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next to the probe) and lack of photoluminescence and
transparency.47
To fully quantify the performance of the design and the
behavior of the bolt in situ, FEA provided insightful simulation
of the mechanical properties of the frontal bone, the curvature
of the skull at Kocher’s point (the traditional default position
for intracranial access) and friction between the two bodies
(Figure 1b). The simulation also enabled the identification of
points susceptible to fracture, optimization of material
selection, and design parameters (Figure S2 and Tables S1−
S3). The key performance indicators (KPIs), which guided the
design optimization and enabled the interpretation of the
simulation results are summarized in Table 2, where the
maximum displacement difference (MDD) quantifies the
degree of fracture and minimum safety factor (SF) quantifies
the risk of fracture and device failure.48
We have used various event simulations to investigate the
effects of material selection on the basis of a thread length of 7
mm (Figure S2 and Tables S1−S3). The key indicators of
design optimization included the minimization of heteroge-
neous deformation or displacement across the device and the
mitigation of the device fracture. The materials investigated in
Figure 1. Probe design. (a) Clip is used to aid device positioning and probe alignment: (i) cross-sectional analysis of the Raman probe housing and
thread. Note the dimensions of the screw thread and the relation to site parameters detailed in Table 1. (ii) Cross-sectional analysis of the clip and
baffle slots. (iii) Tightening and alignment clip fitted to the probe housing. (iv) Aerial view of the clip. (b) In situ analysis of the bolt: (i)
approximation of the frontal bone at Kocher’s point. (ii,iii) Top and side views of simulation. (iv) Implementation of load and constraints. (c)
Section analysis of the housing (left) to demonstrate the internal ledge and drawing of top view of the probe housing (right), with the dimensions
of the ledge indicated. (d) Points of high stress in ABS and fracture propagation at the bolt joint. The legend is indicative of the von Mises stress
developed in the structure.
Table 2. KPIs Used in Simulations
KPI equation simulation type




SF yield stress/working stress static stress
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simulations included ABS, polyamide 6 (PA6), and titanium
6AI-4V. ABS was chosen for its properties as a thermoplastic,
which are similar to the prototyping material, that is, the PLA
and biocompatibility.49 Nylon 6 can be further considered as a
potential material given the recommended use in medical
devices with short-to-medium term contact applications in
conjunction with its material properties.50 Titanium is a
renowned biomedical material, primarily for its effective
integration with tissue, reducing fibrous tissue growth and
scarring around implants.51 Combined with the modern
stereo-lithography methods, device fabrication should take
advantage of both the biocompatibility and strength of the
material for a given application.52 Outputs from the event
simulations are summarized in Table 3, where the maximum
variance of displacement is defined as the difference between
the displacement of the thread and probe housing and
quantifies the degree of crack propagation at the joint. From
the simulations, it was established that titanium poses little risk
of fracture even under loads of 1.6 Nm. On the other hand,
both ABS and PA6 exhibit fracture at lower loads, with PA6
deforming less than ABS.
In the early prototyping and development of the skull model,
it became apparent that the internal ledge formed in the
craniotomy procedure would provide an obstruction to
implementation of the device even once removed. Fracture
of device prototypes was often observed with complex skull
curvature, and friction between the thread and skull is
hypothesized to be the major factor. Hence, we used the
static stress analyses to investigate the effect of thread length,
which is equivalent to varying the area for frictional contact in
situ. Thread lengths of 5 and 7 mm were investigated, with the
step change between the two, equivalent to the thickness of the
internal ledge, as detailed in Table 1. In all simulations, ABS
was chosen as the device material (Figure 2 and Table 3).
The equivalent of 0.8 Nm and a minimum of SF > 1
indicates the device is safe for general application. However, a
minimum of SF ≥ 4 is typically recommended in the literature
to minimize risk in medical applications.53,54 Upon static stress
analysis of the 5 mm thread length using titanium 6AI-4V, a
minimum SF of 11.58 was achieved. The points of greatest
induced stress and fracture propagation are shown in Figure
1d. These results indicate that the ABS is not an optimal
choice for future design; however, PA6 and titanium are found
to be both suitable materials for this purpose. For the in-
patient utilization of these materials, further optimization
should consider material selection in the scope of treatment
viability, device utility, and cost.
Subsequent to the prototype design, the setup was tested for
its potential to act as a clinical in vivo device. A skull model was
developed through the creation of a craniotomy site via
conventional neurosurgical tools, 3D printing, and insertion of
a sample holder internal to the calvarial vault (Figure 2). The
device with the probe was then inserted into the site of
interest, and the in situ measurements were carried out.
Raman spectra were acquired using the experimental
geometry, as shown in Figure 3, which allowed coupling the
output fiber of the probe to a portable Raman spectrometer. In
this configuration, the spectrum was collected by focusing onto
the output of the probe collection fiber (held axially using a 3D
printed holder) and a Raman acquisition sequence was run
using the WiRE software. The diameter of the probe (Table 1)
Table 3. Event Simulation Outputs and Minimum SF








ABS 2828 45.16 0.8
PA6 832 70.74 0.96
titanium 86 N/A N/A
simulation thread length (mm) min. SF
SS-7 7 2.60
SS-8 5 3.32
aComparative analysis in thread length is made with respect to
simulations with ABS as the device material.
Figure 2. Development of a skull model. (a) Fully assembled model.
(b) Sample holder internal to the skull. (c) Sample holder at Kocher’s
point. (d) Medical device in situ.
Figure 3. Performance of the device. Validated by collecting the
output signal from the distal end of fiber using the spectrometer as a
detector and the probe arrangement using the skull model.
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being smaller than that of the bolt enables it to be easily
incorporated into a standard of care (Figure S3).
Using this setup, we successfully demonstrate that spectra
obtained through the developed device design reliably
reproduce the information measured from commercial
Raman microscopes (e.g., inVia Renishaw) (Figure 4a). The
effects of fluorescence in the early acquisition of spectra, under
typical exposure and laser power (5−25 s, 20−30 mW), were
minimized through the development of a specific acquisition
sequence in combination with the optimization of the probe’s
distance from the sample (Table 4). Data collection was
carried out via the Raman setup in conjunction with the bolt
and skull model, and the key considerations which guided the
correct parameter selection were determined by the maximum
achievable signal-to-noise ratio and a minimum risk of laser
damage to sample, which enabled collection of a large number
of high quality of spectra with a negligible effect of fluorescence
through the utilization of a longer wavelength source.
Building upon our recently established murine model of
direct cortical TBI impact,39a,b demonstrating the differ-
entiation between TBI, the healthy controls amongst differing
states of injury severity, the measured key bands of murine
tissue used to simulate the spectral response from the brain,
show corresponding changes with TBI including dominant
bands at 1266, 1447, and 1660 cm−1 (Figure 4a,b), which are
attributed to cellular metabolic distress and dysfunction. These
bands are representative of C−C aromatic ring stretching
associated with fatty acids that comprise certain lipids in the
brain, the in-plane bending of CH2 and CH3 (asymmetric)
bonds present in lipids and proteins constituting what is likely
to be gray matter and the CO and CC coupled bond
stretching in unsaturated fatty acid residues, respectively.44,55
Changes to lipid composition in response to TBI (post-fixed
tissue, 3 days after injury) determined by non-negative least
squares fitting have shown previously that the coefficients for
each lipid spectrum were proportional to the concentration
measured within each sample,39b,44 with the main statistically
significant differences arising from cholesterol and cardiolipin,
where a reduction in the latter is linked to the decrease in
bands at 1266 and 1660 cm−1 for TBI. The regression
coefficients for the cardiolipin, ganglioside, and hemoglobin
Figure 4. Spectroscopic performance. (a) Raman spectra from the developed intracranial spectroscopic setup with coupled output fiber from the
probe (red) vs the microscope objective (blue), allowing measuring the performance of the probe and the skull model. (b) Representative spectra
from TBI (red) compared to the healthy controls (black) in murine brain tissue (785 nm, 20 mW, 3−5 s) with specific bands highlighted at 1266,
1447, and 1660 cm−1 and (c) changes to relative lipid composition as a result of severe (sTBI), moderate (mTBI) vs control.39 The boxplots show
the non-negative least squares regression coefficient fitted to the average spectrum collected from each sample (p < 0.05). (d). SOM clustering of
Raman spectra from for TBI (red) and control (black) cohort.
Table 4. Acquisition Parameters of the Probe
parameter probe value
spectral domain (cm−1) −200 to 3723
laser wavelength (nm) 785
laser power (mW) 20−30
exposure (s) 5−25
accumulations 15
probe distance from sample
(mm)
7.5 (equal to working distance of the
probe)
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(Figures 4c and S4) show insights into the separation of injury
classes, with a larger coefficient indicating a greater
contribution to the spectra. It is of note that the coefficients
related to mild TBI observe a greater variance given the
complexities and natural variation of biochemical response
associated. Further to the discernible differences in peaks from
Raman spectra, machine learning algorithms were applied to
extract the subtle spectral changes present. Short acquisition
times, representing the real-world conditions, meant that
individual spectra used as training inputs exhibited only minute
changes, which via SKiNET were used to accurately identify
TBI versus control groups (Figure 4d), where the neurons are
grouped according to particular features, with each hexagon in
the SOM being colored according to the type of data it
activates, that is, control (black) versus the TBI (red),
providing visualization on the data classification. The
preformed fitting of raw component spectra from brain specific
lipids correlates to the SOMDI for a particular state (Figure
S4a,b). The subtle changes identified via SKiNET to spectral
features in the analysis of Raman spectra show a clear
separation between TBI and control groups (Figure 4d).
■ DISCUSSION
In TBI disease state, the relative ratio of the 1447/1660 cm−1
peak height is found to be considerably increased and
correlating with the injury severity (Figures 4b, S4, and S5).
Previous studies have demonstrated that white matter presents
a broad Raman shift in the region of 1200−1350 cm−1 with
similar normalized intensity to the 1660 cm−1 peak, whereas
gray matter does not.56 However, the peaks were often much
lower in intensity relative to the 1447 cm−1 band. It is
therefore reasonable to note that an important confoundment
to the findings relating to 1447/1660 cm−1 ratios could be the
model itself. The direct cortical injury model is an energy-
focused model, with increasing energy of strike to the cortical
surface. A possible explanation to not seeing a progressive
difference in the height of these peaks is that the surface injury
from each strike (regardless of energy) inflicts similar injury to
the brain surface (injury saturation in effect). A focal surface
measurement in these cases may not be ideal.
However, a one-way analysis of variance analysis shows a
statistically significant difference in the contribution from
cardiolipin compared to the control (Figure 4c), which is
linked to the increase in the ratio of bands at 1447 and 1660
cm−1 in Figure 4b in TBI for both moderate and severe TBI
versus the control group. A statistically significant change is
also observed between injury severity for cardiolipin and exists
in ganglioside for mTBI compared to control. However, there
is no statistically significant difference between mTBI and sTBI
in this case. Small coefficients were fitted for hemoglobin for
sTBI and mTBI but were not statistically significant. The
hemoglobin change is most probably a result of hemorrhage,
yielding an increase in its concentration specific to the injury
site. It has been reported that cardiolipin undergoes oxidation
during the pathophysiological cascade in TBI, with an
accumulation of similar oxidation products in the region of
injury.57,58 An accumulation of ganglioside in the region of
injury has also been demonstrated.42 Temporal changes from
direct analyses of brain tissue have been previously studied by
Surmacki et al.59 using the murine TBI model. Cardiolipin,
playing a key-role in cell metabolism and signaling, has been
shown to compromise the blood brain barrier, triggering the
metabolic disruption and the biochemical cascade following
TBI cell damage, resulting in its release.60 These results are
further consistent with study by Tay et al., where the authors
identified a link between the observed spectral changes and
apoptosis via comparison to immunohistochemistry of TBI in
mice using Raman spectroscopy.33 Consistent changes are
observed to spectra in response to injury, and particularly, in
the 1266 cm−1 relative to the 1447 and 1660 cm−1 bands,
which are proportional to injury severity (Figures S4 and S5).
These findings are in correspondence with the subtle changes
seen in the previous study by Surmacki et al. Similar peaks
were identified as strong SOMDI weights as derived from
analysis provided by SKiNET (Figure 4d). These weights are
associated with each group at 1003, 1266, 1337, 1447, and
1660 cm−1 representing, skeletal C−H of phenylalanine, C−C
bending of mixed proteins/lipids, C−N stretching, N−H
bending of the amide III, C−H2 bending, and CC stretching
of the proteins and lipids, in correspondence with the Figures
S4−S6 and the literature.33,39,42,56−58
It is worth noting that invasive intracranial monitoring
devices tend to be used within the context of severe TBI where
there is a clear indication for neuro-protective sedation.
Typically, these are used in the acute phase of injury in
which invasive monitoring takes place and is considered to be
between 3 and 5 days. However, there are common
exemptions, and a number of devices are licensed to be in
situ for up to 2 weeks. Our device would be analogous to
incorporate the current standard of invasive monitoring care.
This would be inserted at presentation and remain in situ
during the acute phase of injury evolution (between 2 and 7
days depending on secondary injury evolution). The
accumulation of inflammatory debris might play a factor at
the optical interface. To mitigate this, a saline flush,
representing a reflective isotonic environment, a self-cleaning
conduit, or mechanical (iris pattern open and close) sweep can
be integrated into the design such as those used in cerebral and
ven t r i c u l a r endo s cope s , comb ined w i t h po l y -
(tetrafluoroethylene) and or other anti-adhesion coatings. A
further possibility will be to use an anti-fouling coating, such as
for instance the Surphys 009, which has been previously shown
to considerably reduce a stent bacterial counts compared to
controls with decreased pathogen adherence.60 Light absorp-
tion by water in the wavelengths described in our study is
minimal; therefore, tissue heating at this irradiance using the
785 nm laser, the laser power, and the exposure time (Table 4)
will cause negligible if any tissue damage. Similar intensities of
light are already used in direct to tissue oxygen tension,
including for instance, the Raumedic PbtO2 measurements via
fluorescence quenching, with a safety profile similar to other
invasive monitoring modalities.61
■ CONCLUSIONS
We have designed, engineered, and characterized a novel
proof-of-concept device to in situ track the biochemical
changes of brain composition under the pathophysiological
cascade associated with TBI via Raman spectroscopy.
Titanium 6AI-4V has been established as a preferable material
of fabrication with the final design consisting of an M15 × 1.5
thread of 5 mm in length adjoined to a probe housing. Static
stress analysis of the design, when printed in titanium 6AI-4V,
revealed a minimum SF of 11.58. The utilization of this
material has obvious performance and biocompatibility
benefits; however, further optimization should be considered
for material selection in the scope of treatment viability, device
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utility, and cost. A skull model has also been developed, which
has highlighted the potential for clinical translation of the
design in view of complex skull curvature. Spectra obtained
from the design setup accurately reproduce those acquired
with the standard commercial Raman system, and the collected
signal demonstrates that they are comparable in terms of
quality and the detected bands to the TBI model, reliably
retrieving subtle, specific biochemical changes to those
typically measured using the commercial Raman microscope.
This proof-of-concept device provides a clear demonstration
that Raman spectroscopy of brain cortex has the potential to
provide an added value within the context of clinical
monitoring and improved management of TBI. A great deal
of investigation was carried out to quantify properly the use of
the Raman spectra to stratify injury severity and resolve the
evolution of pathology prior to any form of clinical testing or
introduction; however, we demonstrate here the concept in its
most basic form. It also lays a platform for further
developments of probe design via for instance, including an
ICP monitor with other standards of care, to aid clinical
integration and translation of the device into clinic by
removing the need for any further intracranial access burden.
Ultimate integration of such a tool with emerging artificial
intelligence techniques, such as our recently developed
SKiNET method will further provide important interpretable
therapeutic and management guidance. Real-time, rapid in vivo
spectroscopic brain measurements in TBI patients will enable
establishing insights into biological pathways underlying the
associated neurological pathophysiology and could conceivably
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